Literature DB >> 32548138

Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status.

Kentaro Tominaga1, Kenya Kamimura2, Hiroki Sato1, Masayoshi Ko1, Yuzo Kawata1, Takeshi Mizusawa1, Junji Yokoyama1, Shuji Terai1.   

Abstract

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis clinically characterized by the presence of painful skin ulcerations with erythematous. As it is frequently associated with inflammatory bowel diseases, including ulcerative colitis, gastroenterologists should be familiar with the disease including therapeutic options. Therefore, we have conducted a review focusing on the cytapheresis for PG in cases of inflammatory bowel diseases. A literature search was conducted to extract studies published in the last 20 years, with information on demographics, clinical symptoms, treatment, and the clinical course from a total of 22 cases reported and our recent case. In most patients, cytapheresis was associated with improvement or resolution of PG after failure of conventional therapeutic options such as corticosteroids, antibiotics, immunosuppressive agents and immunoglobulin. Based on the information summarized, cytapheresis is helpful in the majority of patients with PG refractory to medical treatment associated with inflammatory bowel diseases and could be further studied in a multicenter, randomized trial. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Complications; Cytapheresis; Granulocytapheresis; Inflammatory bowel diseases; Leucocytapheresis; Pyoderma gangrenosum

Year:  2020        PMID: 32548138      PMCID: PMC7281039          DOI: 10.12998/wjcc.v8.i11.2092

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  33 in total

1.  Treatment of pyoderma gangrenosum associated with Crohn's disease.

Authors:  Toshihide Ohmori; Akio Yamagiwa; Itaru Nakamura; Kou Nishikawa; Abby R Saniabadi
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

2.  Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis.

Authors:  Tamihiro Kawakami; Masahide Yamazaki; Yoshinao Soma
Journal:  Am J Gastroenterol       Date:  2009-09       Impact factor: 10.864

3.  Beneficial effects of neutrophil-targeted therapy for pyoderma gangrenosum associated with ulcerative colitis.

Authors:  Kazuko Ikeda; Toshihisa Hamada; Masaki Otsuka; Keiji Iwatsuki
Journal:  Eur J Dermatol       Date:  2011 Sep-Oct       Impact factor: 3.328

Review 4.  Pyoderma gangrenosum: a systematic review.

Authors:  E Cozzani; G Gasparini; A Parodi
Journal:  G Ital Dermatol Venereol       Date:  2014-10       Impact factor: 2.011

5.  Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis.

Authors:  Irene Russo; Serena Miotto; Anna Colpo; Piero Marson; Tiziana Tison; Anna Ferrazzi; Mauro Alaibac
Journal:  Int Wound J       Date:  2016-10-28       Impact factor: 3.315

Review 6.  Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders.

Authors:  Takuro Kanekura
Journal:  J Dermatol       Date:  2018-05-21       Impact factor: 4.005

7.  Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis.

Authors:  Osamu Nomura; Taro Osada; Tomoyoshi Shibuya; Dai Ishikawa; Keiichi Haga; Tomohiro Kodani; Naoto Sakamoto; Tatsuo Ogihara; Ken Yamaji; Sumio Watanabe
Journal:  J Clin Apher       Date:  2017-06-05       Impact factor: 2.821

8.  Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.

Authors:  Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

Review 9.  Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.

Authors:  A Agarwal; J M Andrews
Journal:  Aliment Pharmacol Ther       Date:  2013-08-05       Impact factor: 8.171

10.  Leukocytapheresis treatment for pyoderma gangrenosum.

Authors:  E Fujimoto; N Fujimoto; K Kuroda; S Tajima
Journal:  Br J Dermatol       Date:  2004-11       Impact factor: 9.302

View more
  1 in total

Review 1.  Use of granulocyte and monocyte adsorption apheresis in dermatology (Review).

Authors:  Laura Gnesotto; Guido Mioso; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2022-06-24       Impact factor: 2.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.